List of Excipients in Branded Drug LABETALOL HCL IN SODIUM CHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	LABETALOL HCL IN SODIUM CHLORIDE	labetalol hydrochloride	0143-9363	ANHYDROUS DEXTROSE
Hikma Pharmaceuticals USA Inc	LABETALOL HCL IN SODIUM CHLORIDE	labetalol hydrochloride	0143-9363	CITRIC ACID MONOHYDRATE
Hikma Pharmaceuticals USA Inc	LABETALOL HCL IN SODIUM CHLORIDE	labetalol hydrochloride	0143-9363	EDETATE DISODIUM
Hikma Pharmaceuticals USA Inc	LABETALOL HCL IN SODIUM CHLORIDE	labetalol hydrochloride	0143-9363	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	LABETALOL HCL IN SODIUM CHLORIDE	labetalol hydrochloride	0143-9363	SODIUM HYDROXIDE

Labetalol HCl in Sodium Chloride: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 22, 2026

Labetalol hydrochloride in sodium chloride is an established intravenous beta-adrenergic blocker formulation used primarily for acute hypertension, including perioperative hypertension and hypertensive emergencies. Its active pharmaceutical ingredient is off-patent, and the commercial opportunity is concentrated in ready-to-administer presentations, stability, container-closure systems, hospital procurement, and differentiated supply reliability rather than in new-molecule exclusivity.

The formulation is technically simple: labetalol hydrochloride in an aqueous sodium chloride vehicle, generally using 0.9% sodium chloride injection. The main development risks are chemical stability, pH control, precipitation, extractables and leachables, particulate control, and compatibility with infusion systems.

What is labetalol hydrochloride in sodium chloride injection?

Labetalol hydrochloride is a combined alpha-1 adrenergic antagonist and nonselective beta-adrenergic blocker. Intravenous labetalol is administered when rapid blood-pressure reduction is required and oral therapy is unsuitable or insufficient.

Commercial presentations include:

Attribute	Typical profile
Active ingredient	Labetalol hydrochloride
Route	Intravenous injection or infusion
Common concentration	5 mg/mL
Common presentation	100 mg/20 mL vial or equivalent container
Diluent	0.9% sodium chloride injection
Therapeutic area	Acute hypertension, perioperative hypertension
Regulatory category	Abbreviated new drug application or legacy approved product
Patent status	Active-ingredient patents expired
Primary commercial differentiator	Ready-to-use supply, stability, packaging, and hospital distribution

FDA labeling for labetalol hydrochloride injection describes dilution in compatible intravenous fluids, including sodium chloride injection, when infusion administration is required. Product-specific labels control the permitted concentration, storage conditions, dilution instructions, and handling requirements.[1]

What excipients are used in labetalol HCl in sodium chloride?

The central excipient is sodium chloride, which provides an isotonic aqueous vehicle. Depending on the product, the formulation may also contain pH-adjusting agents, although not every presentation discloses an extensive excipient system.

A typical formulation strategy is:

Excipient or component	Function	Key development issue
Sodium chloride	Tonicity adjustment and aqueous vehicle	Osmolality, crystallization, container compatibility
Water for injection	Solvent	Sterility, endotoxin, conductivity
Hydrochloric acid or sodium hydroxide	pH adjustment	Stability, local tolerability, precipitation control
Nitrogen overlay, where used	Oxygen reduction	Oxidative degradation and headspace control
Container-closure system	Product protection	Sorption, leachables, light and oxygen transmission

The formulation should avoid unnecessary excipients. Labetalol hydrochloride is sufficiently soluble for an aqueous injectable product, reducing the need for co-solvents, surfactants, or complexing agents. A minimal excipient composition can simplify regulatory review, reduce incompatibility risks, and support hospital adoption.

What pH range is important?

The target pH should be established through forced-degradation, long-term stability, accelerated stability, and compatibility studies. The commercial product label should control the final specification. A formulation developer should not assume that a broader pH range is acceptable merely because labetalol remains visually soluble.

Critical evaluations include:

• Assay and related substances over time
• Solution color and clarity
• Subvisible and visible particulate matter
• pH drift
• Osmolality
• Container-closure integrity
• Compatibility with common infusion bags and tubing
• Adsorption to administration sets
• Stability after dilution
• Photostability
• Freeze-thaw performance

Labetalol hydrochloride contains aromatic and amine functionality that can create degradation pathways sensitive to pH, oxygen, light, and temperature. The formulation should be evaluated for oxidative degradation and any increase in impurities caused by contact with elastomers, plastic bags, or closure components.

What formulations are protected by patents?

The original labetalol composition and core pharmaceutical use patents have expired. A new product would not generally obtain composition-of-matter exclusivity for labetalol hydrochloride.

Potentially protectable subject matter remains in narrower areas:

1. Ready-to-administer premixed solutions.
2. Specific concentration ranges.
3. Stability profiles under defined storage conditions.
4. Low-impurity formulations.
5. Oxygen-controlled or nitrogen-purged manufacturing.
6. Light-protective packaging.
7. Plastic container systems.
8. Extended in-use stability after opening or dilution.
9. Terminal sterilization or aseptic-processing methods.
10. Hospital workflow systems linked to dosage and administration.

The commercial value of these patents depends on claim breadth. A patent limited to a particular pH, concentration, or packaging material may be difficult to enforce if competitors can use an alternative formulation. A patent covering a measurable stability profile or a distinctive container system may create greater practical differentiation, but it must withstand obviousness and enablement challenges.

No material patent barrier should be assumed solely from the presence of formulation patents. Patent validity, claim construction, prosecution history, and market overlap determine the actual blocking position.

What is the Orange Book status of labetalol hydrochloride injection?

Labetalol hydrochloride injection is an off-patent small-molecule product. The principal regulatory pathway for a new generic injectable product is an ANDA, subject to FDA requirements for pharmaceutical equivalence, bioequivalence or applicable waiver, sterility, strength, quality, labeling, and manufacturing controls.

Relevant regulatory points include:

Regulatory issue	Commercial impact
Orange Book listing	Determines listed patents and certifications for applicable reference products
Paragraph IV challenge	Relevant only if an unexpired listed patent blocks approval
Paragraph III certification	Approval may be deferred until patent expiration
Section viii statement	May be relevant where patented uses are carved out
Injectable ANDA review	Emphasizes sterility, particulate control, manufacturing, and container closure
Drug shortage review	Reliable supply can improve procurement position
180-day exclusivity	Possible for a qualifying first Paragraph IV filer, but unlikely to create value where no blocking patent remains

The active ingredient is not subject to biosimilar competition because labetalol is a conventional small molecule, not a biologic. The competitive threat is from generic injectable manufacturers and hospital compounding operations, not biosimilar applicants.

When does labetalol lose exclusivity?

Labetalol lost regulatory and patent exclusivity years ago. Current commercial protection does not depend on new-molecule exclusivity. Any remaining product-specific exclusivity would need to arise from a later-approved formulation, delivery system, pediatric indication, or other qualifying innovation.

For a conventional labetalol hydrochloride in sodium chloride injection, the main barriers are operational:

• FDA-compliant sterile manufacturing
• Validated aseptic processing
• Reliable availability of glass vials, plastic bags, or syringes
• Low particulate burden
• Consistent impurity control
• Acceptable stability dating
• Hospital formulary approval
• Competitive wholesale pricing

These barriers can protect market share even when legal exclusivity is absent.

How strong is the patent estate for labetalol HCl in sodium chloride?

The patent estate is weak for the active ingredient and potentially moderate for differentiated presentation technology.

Patent layer	Strength	Commercial assessment
Composition of matter	Very low	Expired
Basic injectable solution	Low	Likely vulnerable to invalidity or design-around arguments
Sodium chloride vehicle	Very low	Standard pharmaceutical practice
Specific pH or concentration	Low to moderate	Narrow scope and design-around risk
Stability-improving packaging	Moderate	Stronger if tied to measurable performance
Ready-to-administer system	Moderate	May support product differentiation
Manufacturing process	Moderate	Enforcement depends on proof of process use
Device or closed-system delivery	Moderate to high	More valuable if integrated into hospital workflow

A robust portfolio would combine formulation claims with container, manufacturing, and use claims. A single claim directed only to "labetalol hydrochloride in sodium chloride" would likely have limited commercial durability because the ingredients and dosage form are conventional.

What excipient strategies create commercial opportunities?

Ready-to-administer premixed bags

A premixed bag can eliminate bedside dilution and reduce medication-preparation steps. The value is highest in emergency departments, intensive-care units, operating rooms, and transport settings.

Commercial advantages include:

• Lower pharmacy compounding workload
• Reduced calculation and dilution errors
• Faster administration
• More consistent concentration
• Better inventory standardization
• Potential reduction in waste from partial vials

The principal development challenge is achieving sufficient shelf life in the final container. The product must be assessed in flexible bags, multilayer films, and administration sets, not only in laboratory glass.

Unit-dose syringes

Ready-to-use syringes can target emergency carts, operating rooms, and procedural areas. They may support higher pricing than bulk vials because they provide labor savings and dose standardization.

The excipient system remains simple, but the device introduces new risks:

• Silicone oil or lubricant interaction
• Needle and stopper compatibility
• Syringe barrel adsorption
• Plunger movement over shelf life
• Extractables and leachables
• Dose-volume accuracy
• Human-factors compliance

Extended stability after dilution

A product with validated stability after dilution in common infusion fluids could reduce pharmacy waste. The label must distinguish unopened-product shelf life from in-use stability after dilution or withdrawal.

Potentially valuable studies include stability in:

• 0.9% sodium chloride
• 5% dextrose
• Polyolefin bags
• PVC tubing
• Glass containers
• Common elastomeric closures
• Standard infusion pump systems

The commercial claim should be based on validated chemical and physical stability, not visual appearance alone.

Low-oxygen formulation and packaging

Oxygen-control measures can include nitrogen purging, low-headspace filling, oxygen-barrier films, and light-protective overwraps. These approaches may reduce oxidative degradation and extend dating.

A patent strategy could claim the combination of:

• Labetalol hydrochloride concentration
• Sodium chloride concentration
• Defined dissolved-oxygen limit
• Specific pH range
• Container oxygen-transmission rate
• Impurity threshold after storage

Such claims are more commercially meaningful than a broad claim to the active ingredient in saline.

Preservative-free packaging

Preservative-free single-dose presentations are aligned with intravenous hospital use and reduce concerns about preservative exposure. A preservative-free product can be differentiated through a vial, bag, or syringe platform that supports aseptic withdrawal and minimizes microbial risk.

Multi-dose packaging may reduce packaging cost but introduces preservative, sterility, and in-use handling issues. It is less attractive for emergency injectable use unless the clinical setting has strong pharmacy controls.

What manufacturing and intellectual-property barriers exist?

Sterile manufacturing is the primary technical barrier. The product requires validated control of:

• Bioburden
• Bacterial endotoxins
• Particulate matter
• Filter integrity
• Filling accuracy
• Container-closure integrity
• Aseptic interventions
• Environmental monitoring
• Visual inspection
• Stability-indicating analytical methods

A manufacturer can create defensible know-how around impurity formation, oxygen management, filling parameters, and container selection. Trade secrets may be more practical than patents for process conditions that are difficult to detect in a competitor’s finished product.

Packaging supply is a separate risk. A company dependent on one bag film, stopper, syringe, or vial supplier may face interruptions that exceed the value of a narrow formulation patent. Dual sourcing and validated alternative components are commercial assets.

Which companies are likely to compete?

Competition is expected from established generic injectable manufacturers, hospital-supply companies, contract manufacturing organizations, and integrated pharmaceutical distributors. The relevant competitive factors are:

Factor	Importance
FDA-approved sterile capacity	High
National hospital contracts	High
Product availability	High
Backorder performance	High
Ready-to-administer formats	Moderate to high
Unit price	High
Shelf life	Moderate
503B outsourcing capability	Moderate
International registrations	Moderate

The strongest entrants will usually be companies with existing injectable portfolios, established hospital distribution, and redundant sterile capacity. A small developer without its own fill-finish operation may need a contract manufacturing or licensing transaction.

What licensing deals could support commercialization?

The most practical transaction structures are:

1. Formulation license: transfer of a ready-to-use formulation and stability package.
2. Manufacturing license: access to a validated aseptic process and container system.
3. Regional commercialization license: local marketing rights paired with supply obligations.
4. Co-development agreement: shared development of a syringe, bag, or closed-system presentation.
5. Contract manufacturing agreement: supply without transfer of core intellectual property.
6. Hospital-channel partnership: integration with a distributor or group purchasing organization.

Deal value should be tied to measurable assets: regulatory status, stability dating, validated process, approved container, supply history, and hospital contracts. A formulation patent alone is unlikely to justify a substantial upfront payment unless it creates a meaningful approval or market-access advantage.

What generic entry risks exist for labetalol injection?

Generic entry risk is high because the active ingredient is mature and the formulation is relatively straightforward. Price erosion is likely in standard vial presentations.

A differentiated product can reduce direct price competition through:

• Ready-to-administer delivery
• Longer shelf life
• Lower preparation burden
• Lower waste
• Better emergency-department availability
• Smaller or more convenient dose units
• Barcode and electronic medication-administration compatibility
• Improved supply reliability

The principal launch scenarios are:

Scenario	Expected effect
Standard 5 mg/mL vial	Rapid price competition
Premixed infusion bag	Moderate differentiation
Unit-dose syringe	Higher manufacturing cost but stronger workflow value
Long-dated product	Better hospital inventory economics
Shortage-responsive launch	Faster procurement adoption
Specialty regional launch	Lower scale, potentially higher margins

How does labetalol compare with competing injectable antihypertensives?

Labetalol competes with intravenous nicardipine, clevidipine, hydralazine, esmolol, and sodium nitroprusside. The products differ in titration, onset, monitoring requirements, cost, and formulation complexity.

Product	Main advantage	Excipient or formulation opportunity
Labetalol injection	Combined alpha and beta blockade; established use	Premix, syringe, stability, packaging
Nicardipine injection	Continuous titration	Ready-to-use bag and tubing compatibility
Clevidipine emulsion	Rapid titration	Emulsion stability and lipid-system manufacturing
Esmolol injection	Short-acting beta blockade	Premix and high-throughput emergency use
Hydralazine injection	Low-cost intermittent dosing	Unit-dose packaging and supply reliability
Nitroprusside injection	Potent rapid vasodilation	Light protection and degradation control

Labetalol has a simpler aqueous formulation than emulsion-based competitors. That reduces technical complexity but also limits the opportunity to claim novel excipient systems.

What FDA regulatory strategy is most commercially attractive?

The lowest-risk pathway is an ANDA for a formulation matching an approved reference product. A differentiated ready-to-administer product may require additional comparative data, product-specific bioequivalence analysis where applicable, and extensive CMC support.

Priority regulatory workstreams are:

1. Identify the reference-listed drug and approved presentation.
2. Confirm the formulation and container differences permitted under the ANDA pathway.
3. Establish stability-indicating methods.
4. Complete container-closure and extractables/leachables studies.
5. Validate sterility assurance and particulate controls.
6. Generate in-use and dilution compatibility data.
7. Confirm labeling, storage, and administration instructions.
8. Assess drug-shortage and supply-continuity opportunities.

Key Takeaways

• Labetalol hydrochloride in sodium chloride is an off-patent injectable small-molecule product.
• Sodium chloride is the core vehicle; a minimal excipient system is usually commercially preferable.
• Composition-of-matter protection has expired, while formulation and packaging claims may provide narrow differentiation.
• Ready-to-administer bags and unit-dose syringes offer the strongest commercial opportunities.
• Stability, oxygen control, container selection, and in-use compatibility are the main technical value drivers.
• Biosimilar risk is not relevant; generic injectable competition is the principal threat.
• Sterile manufacturing capacity and hospital distribution are more important than active-ingredient patent protection.
• A commercially valuable patent portfolio should cover formulation, packaging, stability performance, manufacturing, and administration systems.
• Product-level revenue estimates are generally unavailable from public sources; commercial potential should be modeled through hospital volume, contract pricing, format mix, and supply reliability.

FAQs About Labetalol HCl in Sodium Chloride

Can labetalol hydrochloride injection be formulated without preservatives?

Yes. A preservative-free single-dose injectable presentation is technically and commercially suitable for intravenous hospital use, subject to validated sterility, container-closure integrity, and in-use handling controls.

Is sodium chloride itself patentable in a labetalol injection?

Sodium chloride as a standard injectable excipient is not a meaningful standalone patent opportunity. Patent value would need to come from a specific formulation, concentration, stability profile, packaging system, or manufacturing process.

Is a premixed labetalol infusion eligible for 180-day generic exclusivity?

Only a qualifying first ANDA applicant that submits an appropriate Paragraph IV certification against an unexpired listed patent could obtain 180-day exclusivity. A conventional off-patent formulation with no relevant unexpired listed patent would not ordinarily create that opportunity.

What is the strongest formulation differentiation for labetalol injection?

The strongest practical differentiation is a ready-to-administer, preservative-free product with extended shelf life, validated dilution compatibility, low particulate levels, and a container system that supports emergency and intensive-care workflows.

Can a 503B outsourcing facility compete with an FDA-approved labetalol injection?

A 503B facility can supply compounded sterile products under the applicable statutory and regulatory framework, but an FDA-approved commercial product generally has advantages in labeling, standardized quality documentation, procurement acceptance, and broad distribution.

References

1. DailyMed. (n.d.). Labetalol hydrochloride injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2014). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. https://www.fda.gov/
4. U.S. Food and Drug Administration. (2014). Guidance for industry: Container closure systems for packaging human drugs and biologics. https://www.fda.gov/
5. United States Pharmacopeia. (2024). General chapter <71>: Sterility tests. In United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.
6. United States Pharmacopeia. (2024). General chapter <788>: Particulate matter in injections. In United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.